Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

XBiotech Q3 2026 Results: Net Loss of $4.46M, Loss Narrows

XBiotech Inc. reported a net loss of $16.7 million for the first nine months of 2026, a slight improvement from the $18.6 million loss in the prior year period. The company's cash position decreased to $105.0 million as of September 30, 2026, while operating expenses were reduced by approximately 32% year-over-year.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Profit before tax-4.4-5.9
Net income-4.5-6.0
EPS (diluted, $ a share)$-0.15$-0.20

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: XBIT. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

XBiotech Inc.: key numbers

Share price
$1.85Close, Nov 16
Market cap
$56.4M
Shares outstanding
30.49MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from XBiotech Inc.

All →
3:49 PM ET Form 4
Insider Buying

XBiotech Director John Simard Buys $143K of Stock

John Simard, Director, bought 70,000 shares of XBiotech Inc. at $2.05 a share, worth $143K in total on Nov 3, 2026. Shares held after the trade: 4,261,690 (+1.7%).

Value
$143K
Shares
70,000
Price
$2.05
Role
Director
Holding change
+1.7%
Trade date
Nov 3, 2026
2:37 PM ET Form 4
Insider Buying

XBiotech Director John Simard Buys $711K of Stock

John Simard, Director, bought 368,524 shares of XBiotech Inc. at $1.93 a share, worth $711K in total on Oct 26, 2026. Shares held after the trade: 4,191,690 (+9.6%).

Value
$711K
Shares
368,524
Price
$1.93
Role
Director
Holding change
+9.6%
Trade date
Oct 26, 2026
9:39 AM ET 8-K
Executive Compensation

XBiotech Executive Compensation

XBiotech has appointed Dr. Sushma Shivaswamy and Jan-Paul Simard as Co-Chief Executive Officers, effective October 23, 2026. Dr. Shivaswamy will maintain her $750,000 annual salary, while Jan-Paul Simard entered into a new employment agreement with a $150,000 base salary and a one-time grant of 2,000,000 stock options vesting over three years.

Term
3 years

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.